Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)

Nature Medicine

Volumn 9, Issue 12, 2003, Pages 1533-1537

  Sereda, Michael W ^a,b   Meyer Zu Hörste, Gerd ^a   Suter, Ueli ^c   Uzma, Naureen ^a   Nave, Klaus Armin ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; MYELIN PROTEIN; ONAPRISTONE; PERIPHERAL MYELIN PROTEIN 22; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 17P; CHROMOSOME DUPLICATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; MALE; MYELINATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SCHWANN CELL; SCIATIC NERVE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; GONANES; HORMONE ANTAGONISTS; HUMANS; MYELIN P0 PROTEIN; MYELIN PROTEINS; PROGESTERONE; RATS; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

ANIMALIA;

EID: 0347185347     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm957     Document Type: Article

References (27)

1. Boerkoel, C.F. et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann. Neurol. 51, 190-201 (2002).
2. Lupski, J.R. et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66, 219-232 (1991).
3. Raeymaekers, P. et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1, 93-97 (1991).
4. Sereda, M. et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16, 1049-1060 (1996).
5. Berger, P., Young, P. & Suter, U. Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics 4, 1-15 (2002).
6. Thomas, P.K. et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120, 465-478 (1997).
7. Garcia, C.A. et al. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology 45, 2090-2093 (1995).
8. Jung-Testas, I. et al. Progesterone as a neurosteroid: synthesis and actions in rat glial cells. J. Steroid Biochem. Mol. Biol. 69, 97-107 (1999).
9. Koenig, H.L. et al. Progesterone synthesis and myelin formation by Schwann cells. Science 268, 1500-1503 (1995).
10. Lin, R.J., Kao, H.Y., Ordentlich, P. & Evans, R.M. The transcriptional basis of steroid physiology. Cold Spring Harb. Symp. Quant. Biol. 63, 577-585 (1998).
11. Desarnaud, F. et al. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J. Neurochem. 71, 1765-1768 (1998).
12. Melcangi, R.C. et al. Progesterone derivatives are able to influence peripheral myelin protein 22 and PO gene expression: possible mechanisms of action. J. Neurosci. Res. 56, 349-357 (1999).
13. Schumacher, M. et al. Progesterone synthesis and myelin formation in peripheral nerves. Brain Res. Brain Res. Rev. 37, 343-359 (2001).
14. Michna, H., Fritzemeier, K.H., Parczyk, K., Nishino, Y. & Schneider, M.R. Antiprogestin-progesterone interactions. Cancer Treat Res. 83, 191-212 (1996).
15. Graham, J.D. & Clarke, C.L. Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res. 4, 187-190 (2002).
16. Edwards, D.P. et al. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol. 53, 449-458 (1995).
17. Butcher, R.L., Collins, W.E. & Fugo, N.W. Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology 94, 1704-1708 (1974).
18. Suter, U. et al. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J. Biol. Chem. 269, 25795-25808 (1994).
19. Magyar, J.P. et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16, 5351-5360 (1996).
20. Huxley, C. et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum. Mol. Genet. 5, 563-569 (1996).
21. Niemann, S., Sereda, M.W., Suter, U., Griffiths, I.R. & Nave, K.A. Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J. Neurosci. 20, 4120-4128 (2000).
22. Perea, J. et al. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10, 1007-1018 (2001).
23. Guennoun, R. et al. Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res. Mol. Brain Res. 90, 75-82 (2001).
24. Pollock, M., Nukada, H. & Kritchevsky, M. Exacerbation of Charcot-Marie-tooth disease in pregnancy. Neurology 32, 1311-1314 (1982).
25. Rudnik-Schoneborn, S., Rohrig, D., Nicholson, G. & Zerres, K. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 43, 2011-2016 (1993).
26. Robertson, J.F., Willsher, P.C., Winterbottom, L., Blamey, R.W. & Thorpe, S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35, 214-218 (1999).
27. Gopalkrishnan, K., Katkam, R.R., Sachdeva, G., Kholkute, S.D., Padwal, V. & Puri, C.P. Effects of ah antiprogestin onapristone on the endometrium of bonnet monkeys: morphometric and ultrastructural studies. Biol. Reprod. 68, 1959-1967 (2003).